Now is an unprecedented time for ambitious action on rare disease, with political momentum reinforced by the work of the current EU Council Trio Presidency, the revision of important EU legislations and recent calls for a new EU action plan. Broad consensus is emerging on some short and long-term opportunities to improve the diagnosis, treatment and care of rare disease patients in Europe by 2030, where innovation will play a central role.
